COVID-19 infection in patients on anti-complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience

Br J Haematol. 2020 Oct;191(1):e1-e4. doi: 10.1111/bjh.17097. Epub 2020 Sep 18.

Authors

Affiliations

¹ Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
² Section of Experimental Haematology, Leeds Institute of Medical Research at St. James's, School of Medicine, University of Leeds, Leeds, UK.
³ Department of Haematology, University Hospital Monklands, Airdrie, Lanarkshire, UK.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Aged
Anemia, Aplastic / complications
Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
COVID-19 / blood
COVID-19 / complications*
Comorbidity
Complement C5 / antagonists & inhibitors*
Complement Inactivating Agents / adverse effects*
Complement Inactivating Agents / therapeutic use
Disease Susceptibility
Fatal Outcome
Female
Hemoglobinuria, Paroxysmal / complications*
Hemoglobinuria, Paroxysmal / drug therapy
Hemolysis
Hospitalization
Humans
Immunocompromised Host
Male
Middle Aged
Pneumonia, Bacterial / etiology
Respiratory Distress Syndrome / etiology
SARS-CoV-2*
Superinfection

Substances

Antibodies, Monoclonal, Humanized
Complement C5
Complement Inactivating Agents
eculizumab
ravulizumab